$317 Million is the total value of Endurant Capital Management LP's 54 reported holdings in Q4 2019. The portfolio turnover from Q3 2019 to Q4 2019 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| NTGN | Exit | NEON THERAPEUTICS INC | $0 | – | -193,052 | -100.0% | -0.12% | – |
| XENT | Exit | INTERSECT ENT INC | $0 | – | -37,815 | -100.0% | -0.23% | – |
| ACHC | Exit | ACADIA HEALTHCARE COMPANY IN | $0 | – | -23,918 | -100.0% | -0.27% | – |
| AXNX | Exit | AXONICS MODULATION TECH INC | $0 | – | -27,759 | -100.0% | -0.27% | – |
| ATRC | Exit | ATRICURE INC | $0 | – | -34,391 | -100.0% | -0.31% | – |
| PETQ | Exit | PETIQ INC | $0 | – | -34,354 | -100.0% | -0.34% | – |
| HUM | Exit | HUMANA INC | $0 | – | -3,899 | -100.0% | -0.36% | – |
| AZN | Exit | ASTRAZENECA PLCsponsored adr | $0 | – | -31,031 | -100.0% | -0.50% | – |
| IIN | Exit | INTRICON CORP | $0 | – | -73,543 | -100.0% | -0.51% | – |
| TAK | Exit | TAKEDA PHARMACEUTICAL CO LTDsponsored ads | $0 | – | -92,273 | -100.0% | -0.57% | – |
| INSP | Exit | INSPIRE MED SYS INC | $0 | – | -30,805 | -100.0% | -0.68% | – |
| BIO | Exit | BIO RAD LABS INCcl a | $0 | – | -6,910 | -100.0% | -0.82% | – |
| SNY | Exit | SANOFIsponsored adr | $0 | – | -67,200 | -100.0% | -1.12% | – |
| SIEN | Exit | SIENTRA INC | $0 | – | -529,950 | -100.0% | -1.23% | – |
| HAE | Exit | HAEMONETICS CORP | $0 | – | -32,594 | -100.0% | -1.48% | – |
| IART | Exit | INTEGRA LIFESCIENCES HLDGS C | $0 | – | -84,225 | -100.0% | -1.82% | – |
| CRL | Exit | CHARLES RIV LABS INTL INC | $0 | – | -74,986 | -100.0% | -3.56% | – |
| JNJ | Exit | JOHNSON & JOHNSON | $0 | – | -107,413 | -100.0% | -4.99% | – |
| HCA | Exit | HCA HEALTHCARE INC | $0 | – | -149,755 | -100.0% | -6.47% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| LABORATORY CORP AMER HLDGS | 31 | Q2 2023 | 8.7% |
| ELEVANCE HEALTH INC | 29 | Q3 2023 | 8.8% |
| BECTON DICKINSON & CO | 28 | Q2 2023 | 9.8% |
| MCKESSON CORP | 27 | Q1 2023 | 4.4% |
| CENCORA INC | 26 | Q3 2023 | 5.9% |
| HOLOGIC INC | 24 | Q3 2023 | 7.5% |
| JOHNSON & JOHNSON | 24 | Q4 2021 | 5.5% |
| ZIMMER HLDGS INC | 23 | Q3 2023 | 7.5% |
| BOSTON SCIENTIFIC CORP | 22 | Q3 2023 | 5.5% |
| DAVITA INC | 22 | Q1 2021 | 4.9% |
View Endurant Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| AZIYO BIOLOGICS, INC. | March 21, 2023 | 576,253 | 4.9% |
| Oxford Immunotec Global PLCSold out | February 17, 2021 | 0 | 0.0% |
View Endurant Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-07 |
| SC 13D/A | 2024-04-10 |
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| SC 13D/A | 2023-09-08 |
| 13F-HR | 2023-08-14 |
| 3/A | 2023-05-24 |
| 13F-HR | 2023-05-15 |
| 3 | 2023-05-15 |
| SC 13D | 2023-05-15 |
View Endurant Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.